X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
The major Asian stock markets have opened the day on an encouraging note. Stock markets in Japan, HongKong and China are trading up by 2.5%, 1.4% and 0.7% respectively. The major stock indices in Europe and US markets ended their previous session in red. The rupee is trading at 65.79 per US dollar.
Indian stock markets have opened the day on an encouraging note. BSE-Sensex is trading higher by 240 points (up 0.9%) and NSE-Nifty is trading higher by 62 points (up 0.8%). Both S&P BSE Midcap and S&P BSE Smallcap, have also opened on a firm note. Both the indices are trading higher by 1% each. Major sectoral indices have opened the day on a positive note with stocks from capital goods, pharmaceutical and metals & mining sectors witnessing maximum buying interest.
As per an article in Livemint, Indian drug regulator is set to draft an amendment to existing pharmaceutical manufacturing laws pertaining to manufacturing practices. The Drug Controller General of India (DCGI) will move a proposal within the next six months to amend the Drugs and Cosmetics Act, 1940. Consequently, the controller general is expected to revisit the existing laws. Reportedly, these efforts are being made to bridge the gap between Indian manufacturing practices and the World Health Organisation's (WHO) good manufacturing practices (GMP). The number of Indian manufacturers following WHO GMP norms is just about 10-15% currently. The GMP norms consist of certain standardization of various aspects in manufacturing. This includes factors such as sanitation and hygiene, qualification and validation, self-inspection, quality audits, suppliers' audits etc. According to the sources, the new regulations will require additional investment of Rs.50 m per facility. This means, the new law could increase the costs of the pharma companies whose facilities are not compliant as per the WHO norms.
As per an article in Economic Times, Hero MotoCorp has unveiled two scooters named 'Maestro Edge' and 'Duet'. Duet is a full metal body scooter. It comprises of a 110 CC engine and will compete directly against Honda Activa. The launch of Mastro Edge is scheduled on October 13. The scooter is priced at Rs 49,500 before local levies and insurance in Delhi. The launch of Duet will follow thereafter. Hero currently has two scooters in its portfolio- 'Pleasure' and 'Maestro'. Both the models were developed using Honda's technology. The new models scheduled to be launch in the upcoming months have been developed inhouse by Hero MotoCorp. Hence it would be interesting to see how well the company is able to garner market share with its own technology. The stock of Hero MotoCorp is trading up by 0.4%.
For information on how to pick stocks that have the potential to deliver big returns, download our special report now!
Read the latest Market Commentary
|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "Indian markets open firm". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!